Dr James Crawley

Publications


Journals

  • Crawley JT; de Groot R. (8 Mar 2012). Cardiovascular string theory. Blood. 119:2181-2182. DOI.
  • Siegerink B; Andersson HM; Luken BM; Crawley JTB; Algra A; Lane DA; Rosendaal FR. (1 Jul 2011). VWF and ADAMTS13 levels and the risk of myocardial infarction and ischaemic stroke in young women: results from the ratio case-control study. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 9:209-209. Author weblink.
  • Yu Y; Crawley JTB; Mason JC; Lane DA. (1 Jul 2011). Protein kinase C isoforms in the divergent endothelial signalling exerted by thrombin- and activated protein c-dependent activation of PAR-1. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 9:239-239. Author weblink.
  • Ahnstrom J; Andersson HM; Canis K; Norstrom E; Yu Y; Dahlback B; Panico M; Morris HR; et alCrawley JTB; Lane DA. (1 Jul 2011). Activated protein S cofactor function of protein S: a novel function for a gamma-carboxyglutamic acid residue. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 9:14-14. Author weblink.
  • Camilleri RS; Cohen H; Mackie IJ; Scully M; Starke RD; Crawley JTB; Lane DA; Machin SJ. (1 Feb 2008). Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 6:331-338. DOI.
  • Andersson HM; Siegerink B; Luken BM; Crawley JT; Algra A; Lane DA; Rosendaal FR. (9 Feb 2012). High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood. 119:1555-1560. DOI.
  • Xiang Y; de Groot R; Crawley JT; Lane DA. (12 Jul 2011). Mechanism of von Willebrand factor scissile bond cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). Proc Natl Acad Sci U S A. 108:11602-11607. DOI.
  • Crawley JT; de Groot R; Xiang Y; Luken BM; Lane DA. (22 Sep 2011). Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood. 118:3212-3221. DOI.
  • Andreou AP; Crawley JT. (Jun 2011). Thrombomodulin analogues for the treatment of ischemic stroke. J Thromb Haemost. 9:1171-1173. DOI.
  • Ahnström J; Andersson HM; Canis K; Norstrøm E; Yu Y; Dahlbäck B; Panico M; Morris HR; et alCrawley JT; Lane DA. (16 Jun 2011). Activated protein C cofactor function of protein S: a novel role for a γ-carboxyglutamic acid residue. Blood. 117:6685-6693. DOI.
  • Smith TJ; Yamamoto K; Kurata M; Yukimori A; Suzuki S; Umeda S; Sugawara E; Kojima Y; et alSawabe M; Nakagawa Y; Suzuki K; Crawley JT; Kitagawa M. (Dec 2010). Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma. Exp Mol Pathol. 89:284-290. DOI.
  • de Groot R; Lane DA; Crawley JT. (21 Oct 2010). The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity. Blood. 116:3064-3072. DOI.
  • Luken BM; Winn LY; Emsley J; Lane DA; Crawley JT. (10 Jun 2010). The importance of vicinal cysteines, C1669 and C1670, for von Willebrand factor A2 domain function. Blood. 115:4910-4913. DOI.
  • Andersson HM; Arantes MJ; Crawley JT; Luken BM; Tran S; Dahlbäck B; Lane DA; Rezende SM. (10 Jun 2010). Activated protein C cofactor function of protein S: a critical role for Asp95 in the EGF1-like domain. Blood. 115:4878-4885. DOI.
  • Pos W; Crawley JT; Fijnheer R; Voorberg J; Lane DA; Luken BM. (25 Feb 2010). An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood. 115:1640-1649. DOI.
  • Crawley JT; de Groot R; Luken BM. (Dec 2009). Circulating ADAMTS-13-von Willebrand factor complexes: an enzyme on demand. J Thromb Haemost. 7:2085-2087. DOI.
  • de Groot R; Bardhan A; Ramroop N; Lane DA; Crawley JT. (28 May 2009). Essential role of the disintegrin-like domain in ADAMTS13 function. Blood. 113:5609-5616. DOI.
  • Konstantinou K; Yamamoto K; Ishibashi F; Mizoguchi Y; Kurata M; Nakagawa Y; Suzuki K; Sawabe M; et alOhta M; Miyakoshi S; Crawley JT; Kitagawa M. (Mar 2009). Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma. Br J Haematol. 144:696-704. DOI.
  • Gardner MD; Chion CK; de Groot R; Shah A; Crawley JT; Lane DA. (29 Jan 2009). A functional calcium-binding site in the metalloprotease domain of ADAMTS13. Blood. 113:1149-1157. DOI.
  • Crawley JT; Efthymiou M. (Jun 2008). Cytoprotective effect of activated protein C: specificity of PAR-1 signaling. J Thromb Haemost. 6:951-953. DOI.
  • Crawley JT; Lane DA; Woodward M; Rumley A; Lowe GD. (Apr 2008). Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost. 6:583-588. DOI.
  • Camilleri RS; Cohen H; Mackie IJ; Scully M; Starke RD; Crawley JT; Lane DA; Machin SJ. (Feb 2008). Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost. 6:331-338. DOI.
  • Crawley JT; Lane DA. (Feb 2008). The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 28:233-242. DOI.
  • Crawley JT. (Sep 2007). Multiple roles of the endothelial cell protein C receptor. J Thromb Haemost. 5:1813-1816. DOI.
  • Crawley JT; Zanardelli S; Chion CK; Lane DA. (Jul 2007). The central role of thrombin in hemostasis. J Thromb Haemost. 5 Suppl 1:95-101. DOI.
  • Lam JK; Chion CK; Zanardelli S; Lane DA; Crawley JT. (May 2007). Further characterization of ADAMTS-13 inactivation by thrombin. J Thromb Haemost. 5:1010-1018. DOI.
  • Chion CK; Doggen CJ; Crawley JT; Lane DA; Rosendaal FR. (1 Mar 2007). ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood. 109:1998-2000. DOI.
  • Mollica LR; Crawley JT; Liu K; Rance JB; Cockerill PN; Follows GA; Landry JR; Wells DJ; et alLane DA. (15 Aug 2006). Role of a 5'-enhancer in the transcriptional regulation of the human endothelial cell protein C receptor gene. Blood. 108:1251-1259. DOI.
  • Zanardelli S; Crawley JT; Chion CK; Lam JK; Preston RJ; Lane DA. (20 Jan 2006). ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem. 281:1555-1563. DOI.
  • O'Donnell JS; McKinnon TA; Crawley JT; Lane DA; Laffan MA. (15 Sep 2005). Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood. 106:1988-1991. DOI.
  • Crawley JT; Lam JK; Rance JB; Mollica LR; O'Donnell JS; Lane DA. (1 Feb 2005). Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood. 105:1085-1093. DOI.
  • Gu JM; Crawley JT; Ferrell G; Zhang F; Li W; Esmon NL; Esmon CT. (8 Nov 2002). Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. J Biol Chem. 277:43335-43343. DOI.
  • Crawley JT; Gu JM; Ferrell G; Esmon CT. (Aug 2002). Distribution of endothelial cell protein C/activated protein C receptor (EPCR) during mouse embryo development. Thromb Haemost. 88:259-266.
  • Ouyang YB; Crawley JT; Aston CE; Moore KL. (28 Jun 2002). Reduced body weight and increased postimplantation fetal death in tyrosylprotein sulfotransferase-1-deficient mice. J Biol Chem. 277:23781-23787. DOI.
  • Luttun A; Lupu F; Storkebaum E; Hoylaerts MF; Moons L; Crawley J; Bono F; Poole AR; et alTipping P; Herbert JM; Collen D; Carmeliet P. (1 Mar 2002). Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 22:499-505.
  • Crawley JT; Goulding DA; Ferreira V; Severs NJ; Lupu F. (1 Feb 2002). Expression and localization of tissue factor pathway inhibitor-2 in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol. 22:218-224.
  • Crawley J; Lupu F; Westmuckett AD; Severs NJ; Kakkar VV; Lupu C. (May 2000). Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol. 20:1362-1373.
  • Carmeliet P; Moons L; Herbert JM; Crawley J; Lupu F; Lijnen R; Collen D. (Nov 1997). Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res. 81:829-839.
  • Crawley J; Lupu C; Das S; Kakkar VV; Lupu F. (1 Jun 1997). In situ expression of tissue factor pathway inhibitor mRNA and antigen in advanced human atherosclerotic lesions. THROMBOSIS AND HAEMOSTASIS. P1664-P1664. Author weblink.

Chapters in books

  • Crawley JTB; Gonzalez-Porras JR; Lane DA. Textbook of Pulmonary Vascular Disease. In Textbook of Pulmonary Vascular Disease. Yuan JX (ed); Garcia JGN (ed); Hales CA (ed). Springer Verlag (May 2009).
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook